Cargando…

Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma

Detalles Bibliográficos
Autores principales:	Kircheva, Diana Y, Husain, Aliya, Watso, Sydeaka, Armato, Samuel, Kindler, Hedy, Vigneswaran, Wickii T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693801/ http://dx.doi.org/10.1186/1749-8090-10-S1-A48

Ejemplares similares

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2014)

Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma
por: Carey, George B, et al.
Publicado: (2012)

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma
por: Tan, Yi-Hung Carol, et al.
Publicado: (2019)

Malignant Pleural Mesothelioma: Current Understanding of the Immune Microenvironment and Treatments of a Rare Disease
por: Tedesco, John, et al.
Publicado: (2022)

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma
por: Lennon, Frances E., et al.
Publicado: (2016)

Successful primary repair of late diagnosed spontaneous esophageal rupture: A case report
por: Kircheva, Diana Y., et al.
Publicado: (2017)

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”
por: Vigneswaran, Wickii T., et al.
Publicado: (2020)

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
por: Loganathan, Sivakumar, et al.
Publicado: (2011)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Update on the pathologic diagnosis of malignant mesothelioma
por: Schulte, Jefree J., et al.
Publicado: (2020)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Systemic Treatments for Mesothelioma: Standard and Novel
por: Kindler, Hedy Lee
Publicado: (2008)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2018)

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
por: Stevenson, James P, et al.
Publicado: (2013)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Marital status as an independent prognostic factor for patients of malignant pleural mesothelioma
por: Pan, Shu, et al.
Publicado: (2022)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

ECM Mechanoregulation in Malignant Pleural Mesothelioma
por: Panzetta, Valeria, et al.
Publicado: (2022)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p89l11ipq8mgfmovg2pfnmvuqd